...
首页> 外文期刊>Bioorganic and medicinal chemistry >Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes
【24h】

Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

机译:发现新型以吡咯为基础的支架,可作为有效的和口服生物利用的游离脂肪酸受体1激动剂,用于治疗2型糖尿病

获取原文
获取原文并翻译 | 示例

摘要

The free fatty acid receptor 1 (FFA1) has gained significant interest as a novel antidiabetic target. Most of FFA1 agonists reported in the literature bearing a common biphenyl scaffold, which was crucial for toxicity verified by the researchers of Daiichi Sankyo. Herein, we describe the systematic exploration of non-biphenyl scaffold and further chemical modification of the optimal pyrrole scaffold. All of these efforts led to the identification of compound 11 as a potent and orally bioavailable FFA1 agonist without the risk of hypoglycemia. Further molecular modeling studies promoted the understanding of ligand-binding pocket and might help to design more promising FFA1 agonists. (C) 2016 Elsevier Ltd. All rights reserved.
机译:游离脂肪酸受体1(FFA1)作为新型的抗糖尿病靶标已引起广泛关注。文献中报道的大多数FFA1激动剂均带有共同的联苯支架,这对第一三共研究人员的验证毒性至关重要。在这里,我们描述了非联苯支架的系统探索和最佳吡咯支架的进一步化学修饰。所有这些努力导致将化合物11鉴定为有效且可口服生物利用的FFA1激动剂,且无低血糖风险。进一步的分子建模研究促进了对配体结合口袋的理解,并可能有助于设计更有希望的FFA1激动剂。 (C)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号